IQVIA completes acquisition of Q2 Diagnostics

By Jenni Spinner contact

- Last updated on GMT

(alphaspirit/iStock via Getty Images Plus)
(alphaspirit/iStock via Getty Images Plus)

Related tags: IQVIA, Diagnostics, Testing, Laboratory, Mergers and acquisitions, Quest Diagnostics

The clinical research tech specialists, which had held 60% of Q2 Diagnostics, will now wholly own the comprehensive clinical laboratory services company.

IQVIA Holdings, which provides analytics, technology solutions and clinical research services to life-science clients, has acquired the remaining 40% of Q2 Solutions from diagnostic information services provider Quest Diagnostics. The companies report that $760m changed hands in the deal, via cash on hand.

Brian O’Dwyer, Q2 Solutions CEO, spoke with Outsourcing-Pharma about the transaction and what it means for both firms, and their industry clients. According to O’Dwyer, IQVIA will benefit from the acquired company’s broad range of services and expertise.

OSP_IQVIAq2_BO
Brian O'Dwyer, CEO, Q2 Solutions

Q2 Solutions leads the industry in their scientific capabilities, providing early engagement support to clients during the design process of their development programs​,” he commented. “It also has a heavy emphasis on innovation, working with clients to create and provide flexible solutions to dynamic changes across the spectrum of laboratory services supporting drug development​.”

O’Dwyer told Outsourcing-Pharma that the company anticipates no planned changes to the structures, leadership or staff at Q2 Solutions as a result of the change in ownership. Furthermore, he said, the newly acquired company will retain its current name and branding.

Q2 Solutions is a comprehensive clinical laboratory services organization providing testing, project management, supply chain, biorepository and biospecimen, and consent tracking solutions for clinical trials. Before this transaction, IQVIA owned a 60% majority share and Quest Diagnostics a 40% minority share of Q2, which was established as a joint venture in 2015.

Though Quest no longer owns any of the newly acquired company, the firm will remain the “strategic preferred laboratory provider” for Q2 Solutions clients, thanks to the terms of a multi-year agreement that calls for the company to deliver a range of complementary lab testing capabilities to that augment Q2 Solutions’ list of core offerings.

Related news

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars